2 days ago
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise.
On September 3, Citigroup **** yst Geoff Meacham highlighted the strategic importance of the Crinetics acquisition, arguing it could diversify Vertex's business while complementing its existing cystic fibrosis franchise and newer businesses in renal disease, hematology, and pain.
Through the transaction, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) gains access to Palsonify (paltusotine), an oral treatment for acromegaly that has already received regulatory approval in Europe. Paltusotine is also in Phase 3 development for carcinoid syndrome **** ociated with neuroendocrine tumors.
Palsonify is particularly important because it provides an immediate commercial revenue opportunity, rather than requiring the company to wait several years for an entirely new drug to reach the market.
Early uptake of Palsonify has been encouraging, supported by expanding physician adoption and improving reimbursement coverage. If that momentum continues, the drug could become an important contributor to Vertex's revenue growth.
#palsonify
On September 3, Citigroup **** yst Geoff Meacham highlighted the strategic importance of the Crinetics acquisition, arguing it could diversify Vertex's business while complementing its existing cystic fibrosis franchise and newer businesses in renal disease, hematology, and pain.
Through the transaction, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) gains access to Palsonify (paltusotine), an oral treatment for acromegaly that has already received regulatory approval in Europe. Paltusotine is also in Phase 3 development for carcinoid syndrome **** ociated with neuroendocrine tumors.
Palsonify is particularly important because it provides an immediate commercial revenue opportunity, rather than requiring the company to wait several years for an entirely new drug to reach the market.
Early uptake of Palsonify has been encouraging, supported by expanding physician adoption and improving reimbursement coverage. If that momentum continues, the drug could become an important contributor to Vertex's revenue growth.
#palsonify
2 months ago
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best healthcare stocks on our list.
TheFly reported on July 2 that UBS ******* yst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target. The ******* yst noted that the stock's 44% decline since mid-January presents an appealing opportunity for investors. UBS highlighted CRNX's pipeline as having multiple potential catalysts, supported by programs with strong chances of clinical success. The firm expressed the highest confidence in the Phase 3 atumelnant program for congenital adrenal hyperplasia and projects peak sales potential of approximately $2.0 billion.
In other news, on July 6, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, representing an equity value of approximately $10 billion, or about $8.8 billion after accounting for estimated acquired cash. The transaction received unanimous approval from both companies' boards and is expected to close in the third quarter of 2026. Vertex stated that CRNX's endocrine-focused portfolio, including PALSONIFY and atumelnant, aligns with its strategy of developing transformative medicines for diseases with significant unmet needs. The acquisition is expected to support Vertex's revenue growth, with the combined ******* ets projected to provide more than $5 billion in potential peak annual revenue.
Crinteics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage biopharmaceutical company focused on developing oral, non-peptide therapies for endocrine diseases and tumors by targeting G-protein-coupled receptors (GPCRs). Its key programs include PALSONIFY (paltusotine), an FDA- and EMA-approved oral treatment for acromegaly; atremelnant, a Phase 3 therapy for congenital adrenal hyperplasia and Cushing's syndrome; and a pipeline targeting conditions such as Graves' disease, obesity, and other endocrine disorders, and this is what makes the company innovative.
While we acknowledge the potential of CRNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
TheFly reported on July 2 that UBS ******* yst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target. The ******* yst noted that the stock's 44% decline since mid-January presents an appealing opportunity for investors. UBS highlighted CRNX's pipeline as having multiple potential catalysts, supported by programs with strong chances of clinical success. The firm expressed the highest confidence in the Phase 3 atumelnant program for congenital adrenal hyperplasia and projects peak sales potential of approximately $2.0 billion.
In other news, on July 6, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, representing an equity value of approximately $10 billion, or about $8.8 billion after accounting for estimated acquired cash. The transaction received unanimous approval from both companies' boards and is expected to close in the third quarter of 2026. Vertex stated that CRNX's endocrine-focused portfolio, including PALSONIFY and atumelnant, aligns with its strategy of developing transformative medicines for diseases with significant unmet needs. The acquisition is expected to support Vertex's revenue growth, with the combined ******* ets projected to provide more than $5 billion in potential peak annual revenue.
Crinteics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage biopharmaceutical company focused on developing oral, non-peptide therapies for endocrine diseases and tumors by targeting G-protein-coupled receptors (GPCRs). Its key programs include PALSONIFY (paltusotine), an FDA- and EMA-approved oral treatment for acromegaly; atremelnant, a Phase 3 therapy for congenital adrenal hyperplasia and Cushing's syndrome; and a pipeline targeting conditions such as Graves' disease, obesity, and other endocrine disorders, and this is what makes the company innovative.
While we acknowledge the potential of CRNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
2 months ago
Interested in Vertex Pharmaceuticals Incorporated? Here are five stocks we like better.
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, paying $85 per share in cash, with closing expected in the third quarter of 2026.
The acquisition adds PALSONIFY, an approved acromegaly treatment, and Atumelant, a Phase 3 candidate for congenital adrenal hyperplasia, expanding Vertex's rare disease pipeline.
Analysts have not yet rerated VRTX shares since the announcement, though H.C. Wainwright maintains a Buy rating with a Street-high $641 price target.
Vertex Pharmaceuticals (NASDAQ: VRTX) recently announced its plans to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $10 billion. The deal, which has already been approved by the board of directors of both companies, is expected to close in the third quarter of 2026.
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, paying $85 per share in cash, with closing expected in the third quarter of 2026.
The acquisition adds PALSONIFY, an approved acromegaly treatment, and Atumelant, a Phase 3 candidate for congenital adrenal hyperplasia, expanding Vertex's rare disease pipeline.
Analysts have not yet rerated VRTX shares since the announcement, though H.C. Wainwright maintains a Buy rating with a Street-high $641 price target.
Vertex Pharmaceuticals (NASDAQ: VRTX) recently announced its plans to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $10 billion. The deal, which has already been approved by the board of directors of both companies, is expected to close in the third quarter of 2026.
